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PreviewsT cells (CTL). Due to the paucity of TIL ex-
tracted from CRC biopsies, functional
interrogation ex vivo was done on TIL
from melanoma biopsies and the authors
found that F. nucleatum inhibited both
CTL and CD4+ T cells. F. nucleatum in-
hibited also IFN-g production by memory
CD4+ T cells in the peripheral blood of
HCMV-infected donors.
In view of such powerfully and wide-
spread ability of some F. nucleatum strains
to inhibit lymphocytes (although the link
between TIGIT binding and hemagglu-
tination is unclear), it is surprising that
F. nucleatum activates NK cells in mice
in a model of periodontitis. The NK cell
receptor NKp46 directly recognized
F. nucleatum, triggeringNKcell production
of TNF-a (Chaushu et al., 2012), a power-
fully inflammatory cytokine that might
lead to bone destruction in the pathogen-
esis of periodontitis, which in turn is also
associated with APO, CVD, and RA. How
can one reconcile the proinflammatory
role of F. nucleatum in the periodontitis
model with the immunosuppression in hu-
man lymphocytes? Fap2 does not bind
mouse TIGIT, and therefore it might be
impossible to untangle in vivo the intri-
cacies of a potential me´nage a trois among210 Immunity 42, February 17, 2015 ª2015 EF. nucleatum, activating NKp46 and inhib-
itory TIGIT. It will also be important to test
whether and how F. nucleatum and other
commensals interact with innate lymphoid
cells (ILCs) other than NK cells, because
ILCs are clearly pivotal in regulating tissue
homeostasis and barrier immunity in res-
ponse to microenvironmental cues, in-
cluding microbes.
While we mull over the chicken and egg
question related towhether F. nucleatum is
the cause or consequence of the condi-
tions it is associated with, the work of
Gur et al. provide a new molecular path-
way that might help guide our thinking on
ways to address the important question
of how commensals turn into pathogens.
Despite the fantastic therapeutic advance
providedby immunecheckpoint blockade,
the response rate of cancer patients is still
far from ideal. With improved microbial
detection technology and due caution for
potential contamination (Salter et al.,
2014), cancer patients might be stratified
according to the presence of bacteria in
the tumor and, by targeting specific bacte-
ria or the inhibitory immunoreceptors they
interact with, one might add a weapon in
the oncologists’ arsenal. Dr. William Coley,
considered one of the founding fatherslsevier Inc.of cancer immunotherapy (reviewed in
Starnes C, 1992), might have found this
approach interesting or dismissed it as a
red herring.
REFERENCES
Chaushu, S., Wilensky, A., Gur, C., Shapira, L.,
Elboim, M., Halftek, G., Polak, D., Achdout, H.,
Bachrach, G., and Mandelboim, O. (2012). PLoS
Pathog. 8, e1002601.
de Andrade, L.F., Smyth, M.J., and Martinet, L.
(2014). Immunol Cell Biol. 92, 237–244.
Gur, I.Y., Isaccson, B., Yamin, R., Jawad, A., Gam-
liel, M., and Enk, J. (2015). Immunity 42, this issue,
344–355.
Han, Y.W. (2015). Curr Op Microb 23, 141–147.
Han, Y.W., Fardini, Y., Chen, C., Iacampo, K.G.,
and Peraino, V.A. (2010). Obstet. Gynecol. 115,
442–445.
Johnston, R.J., Comps-Agrar, L., Hackney, J., Yu,
X., Huseni, M., Yang, Y., Park, S., Javinal, V.,
Chiu, H., Irving, B., et al. (2014). Cancer Cell 26,
923–937.
Liu, H., Redline, R.W., and Han, Y.W. (2007).
J. Immunol. 179, 2501–2508.
Salter, S.J., Cox, M.J., Turek, E.M., Calus, S.T.,
Cookson, W.O., Moffatt, M.F., Turner, P., Parkhill,
J., Loman, N.J., and Walker, A.W. (2014). BMC
Biol. 12, 87.
Starnes, C.O. (1992). Nature 357, 11–12.Mushrooming Insights
into Skin Dendritic Cell PhysiologyKeisuke Nagao1,* and Mark C. Udey1,*
1Dermatology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
*Correspondence: keisuke.nagao@nih.gov (K.N.), udeym@mail.nih.gov (M.C.U.)
http://dx.doi.org/10.1016/j.immuni.2015.01.025
Mechanisms responsible for protective immunity against epicutaneous Candida infections are incompletely
characterized. In this issue of Immunity, Kashem et al. demonstrate that different Candida life forms engage
selected skin dendritic cell subsets in distinct compartments, resulting in qualitatively different immune
responses.Candida albicans is a ubiquitous com-
mensal fungus that colonizes human skin
and mucosal surfaces and also causes in-
fections. Mucocutaneous candidiasis is
a common condition that occurs both in
immune-competent and immunocom-
promised individuals. It has been estab-lished through genetic and immunological
studies that interleukin-17 (IL-17)-me-
diated immunity is critical for protec-
tion against mucocutaneous candidiasis
(Puel et al., 2010, 2011). Patients with
inactivating mutations in IL-17 and the
associated cytokine IL-6 develop a chronicand refractory form of candidiasis termed
chronic mucocutaneous candidiasis
(CMC) (Puel et al., 2011). Rare patients
with APECED (autoimmune poly-
endocrinopathy candidiasis ectodermal
dystrophy,alsoknownasautoimmunepol-
yendocrine syndrome) have neutralizing
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Previewsautoantibodies against IL-17A, IL-17F, and
IL-22 as a result of impaired tolerance
caused by AIRE mutations (Kisand et al.,
2010; Puel et al., 2010). As a consequence
of impaired IL-17-associated immunity,
APECED patients also develop CMC.
Despite the susceptibility of individuals
with IL-17 dysfunction to superficial
Candida infections, impairment of this
aspect of anti-fungal immunity does not
routinely lead to invasive candidiasis.
Invasive candidiasis (manifested by or-
ganisms in visceral organs or the systemic
circulation) is a life-threatening condition
that typically occurs in immunocompro-
mised individuals, including patients with
AIDS and cancer and those receiving
immunosuppressive agents for autoim-
mune and inflammatory diseases or sub-
sequent to organ transplantation. Immune
responses that protect against systemic
candidal infections are not as well charac-
terized as those that mitigate mucocu-
taneous candidiasis. Gain-of-function
mutations in the STAT1 transcription fac-
tor gene lead to defective IL-17 and inter-
feron-g (IFN-g) responses (Sampaio et al.,
2013). This is associated with CMC and
also disseminated coccidioidomycosis
and histoplasmosis. Susceptibility to the
latter two infections is attributed to defec-
tive T helper 1 (Th1) cell responses, sug-
gesting that Th1 cell responses are impor-
tant for protection against systemic fungal
infections in general. Taken together, the
literature suggests that protection against
superficial and invasive fungal infec-
tions is conferred via different defense
mechanisms.
Candida species are dimorphic fungi
that grow as yeast at 30C and as fila-
mentous pseudo-hyphae at 37C. When
organisms from mucocutaneous candidi-
asis lesions are examined by microscopy,
both yeast and pseudo-hyphae can be
observed. Invasive Candida are exclu-
sively pseudo-hyphae. The relative anti-
genicity and virulence of the two Candida
life forms have not been extensively
studied. Whether or not one Candida life
form is more virulent or antigenic than
the other has not been conclusively
determined.
Skin harbors at least three dendritic cell
(DC) subsets that are localized in two
anatomically distinct compartments:
Langerhans cells (LCs) in the avascular
superficial epidermis and CD103+
CD11b and CD11b+ DCs in the vascularunderlying dermis. Despite extensive
study, distinct in vivo functions of LCs
have been difficult to demonstrate. Devel-
opment of mouse models that allow se-
lective depletion of the various skin DC
subsets and carefully controlled studies
of primary T lymphocyte responses to an-
tigens whose distribution can be con-
trolled has allowed for considerable prog-
ress in recent years (Heath and Carbone,
2013). For example, it is now clear that
LCs survey the epidermis for antigens
that have breached the stratum corneum
while maintaining the epidermal tight
junction barrier and subsequently elicit
antigen-specific humoral responses (Ou-
chi et al., 2011) or T cell responses when
the tight junction barrier has also been
disrupted (Igya´rto´ et al., 2011).
Kaplan and colleagues previously
demonstrated that murine skin DCs
promote different types of Th cell im-
mune responses after epicutaneous
C. albicans infection. LCs elicit Th17
cell responses, whereas CD103+ dermal
DCs promote Th1 cell responses. In this
issue of Immunity, Kashem et al. (2015)
go on to demonstrate that the nature of
the Candida life form (yeast versus
pseudo-hyphae) and associated distribu-
tion (epidermis versus dermis) are critical
determinants that influence anti-Candida
immune responses elicited by distinct
skin DCs.
Epicutaneous infection with C. albicans
is facilitated by mechanical disruption of
the stratum corneum via depilation and
sandpaper treatment prior to topical appli-
cation of C. albicans. This protocol results
in localized self-limited skin infections that
are cleared within 1 week (Igya´rto´ et al.,
2011). Antigen-specific T helper cell re-
sponses were measured after epicutane-
ous infection with C. albicans strains that
are genetically modified to express the
peptide antigens 2W1S and Ea, either
constitutively (in yeast and pseudo-hy-
phae) or exclusively in pseudo-hyphae.
The authors confirmed that LCs were crit-
ical for Th17 cell responses andwent on to
demonstrate that IL-6 production by LCs
was required. LCs upregulated IL-6
mRNA expression after epicutaneous
C. albicans infection. Mice whose LCs
were incapable of IL-6 synthesis failed to
induce Th17 cell responses, although
robust Th1 cell responses occurred
(Figure 1). Dectin-1 is a C-type lectin that
is expressed by dendritic cells and bindsImmunity 42,1,3-beta-D-glucan. Protective Th17 cell
responses developed only if C. albicans
was in the yeast form and LCs expressed
Dectin-1.
Dectin-1 has been reported to be crit-
ical for protection against systemic
candidiasis (Marakalala et al., 2013). It is
not obvious how to reconcile this
observation with the concept that
pseudo-hyphae that do not bind Dectin-
1 cause invasive disease (Kashem et al.,
2015). However, Kashem et al. (2015)
did demonstrate that antigen-specific
T cells proliferated in the absence of
Dectin-1-Candida ligation and when
C. albicans that are locked in pseudo-hy-
phae life forms were applied epicutane-
ously. Perhaps C-type lectins other than
Dectin-1 recognize 1,3-beta-D-glucan,
and ligation of these receptors initiates
protective immune responses that have
yet to be defined. Immune responses
against Candida species are likely to be
complex and redundant, potentially
involving other pattern-associated mo-
lecular patterns (PAMPs), pattern-associ-
ated receptors (PARs), immune cells, and
cytokines.
Although Th17 cells prevented epicu-
taneous C. albicans infection, they did
not protect against systemic challenge.
Rather, Th1 cell responses that did not
require IL-6-producing LCs conferred
protection against C. albicans that was
introduced intravenously. One possibility
is that IL-6-deficient LCs interact directly
with T cells to efficiently induce Th1 cell
responses. Alternatively, LC-derived IL-6
or Th17-cell-derived IL-17 might counter-
balance immune responses that are
induced by CD103+ DCs, and loss of
either (or both) of these cytokines results
in prominent Th1 cell deviation (Figure 1).
Kashem et al. (2015) did not determine
whether similar Th1 cell deviation also oc-
curs in Dectin-1-deficient mice or mice
with Dectin-1-deficient LCs. If LC-derived
IL-6 is required for Th17 cell development
and lack of LC-derived IL-6 promotes Th1
cell skewing, LC-targeted immunization
coupled with agonistic or antagonistic
ligation of Dectin-1 could be utilized to
modulate epicutaneous immunity. Alter-
natively, CD103+ DCs could be selectively
targeted to induce Th1 cell responses that
might confer systemic immunity. The re-
ceptor that CD103+ dermal DCs use to
capture C. albicans remains to be
identified.February 17, 2015 ª2015 Elsevier Inc. 211
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Figure 1. Different Candida Life Forms Engage Different Skin DCs to Effect Different Immune Outcomes
In this issue of Immunity, Kashem et al. (2015) demonstrate that epidermal Langerhans cells elicit Th17-cell-mediated immune responses against Candida
albicans in its yeast form via an IL-6- and Dectin-1-dependent manner. Neither Langherhans cells or CD11b+ dermal DCs respond to pseudo-hyphal life forms,
but intradermal injection ofC. albicanswith the Dectin-1 agonist Curdlan enables CD11b+ DCs to elicit Th17-cell-mediated responses. CD103+ dermal DCs elicit
Th1-cell-mediated anti-Candida immune responses via a mechanism that is independent of Dectin-1.
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PreviewsOne of the experiments described in the
present study suggests another potential
vaccination strategy in which Candida
could serve as an adjuvant. When geneti-
cally unmodified C. albicans was intro-
duced epicutaneously in conjunction with
LC-targeted protein antigen delivery
accomplished via anti-Langerin antibody,
mice exhibited robust antigen-specific
Th1- and Th17-cell-mediated responses.
It will be interesting to determine whether
this approach is superior to conventional
vaccines that are injected into skin.
Although CD11b+ DCs were unable to
induce anti-Candida immune responses
after intradermal injection of fungi, co-
inoculation of Curdlan, a bacteria-derived
form of 1,3-beta-D-glucan with infrequent
1,6-linkages, promoted Th17 cell re-
sponses. This indicates that CD11b+ DCs
can also be engaged to induce Th17 cell
responses, representing yet another way
that skin DCs might be manipulated to
generate protective immunity.
Mucocutaneous candidiasis can be
effectively treatedwith topical antifungals.
However, invasive candidiasis in immuno-
compromised patients is difficult to treat
and has high morbidity and mortality.
Most C. albicans are sensitive to triazoles.212 Immunity 42, February 17, 2015 ª2015 EHowever, drug-resistant C. albicans has
become problematic over in recent years
and several non-albicans pathogenic
Candida species (including C. glabrata
and C. kruseii) are inherently resistant to
triazoles (Maubon et al., 2014). Echino-
candins, inhibitors of 1,3-beta-D-glucan
(a cell wall component) synthesis, are uti-
lized in these patients, but acquisition of
resistance to echinocandins is also
emerging (Maubon et al., 2014). Induction
of adaptive immunity against 1,3-beta-D-
glucan via vaccination would be an alter-
native to drug therapies and might be
effective in treating patients who are
infected with drug-resistant Candida
species.
Kashem et al. (2015) provide experi-
mental evidence that distinct Th cell re-
sponses protect against local and sys-
temic Candida infections and that only
yeast elicit local responses, providing a
mechanistic link to human genetic dis-
eases that exhibit susceptibility to
local or systemic Candida infections.
Although further information regarding
Candida strain differences and receptors
that recognize Candida-associated com-
ponents will be important, this study
provides insights that might facilitatelsevier Inc.development of new vaccination strate-
gies to protect against local and sys-
temic Candida infections. After confu-
sion that has persisted for decades,
the amount of definitive information
regarding Langerhans cell function that
we now have access to is ‘‘mushroom-
ing’’ and an increasingly sharp picture
is emerging.REFERENCES
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Understanding of how persistent viral infection impacts humoral immunity is incomplete. In this issue of
Immunity, Wieland et al. (2015) and Yamada et al. (2015) find that high amounts of IgG-antigen complexes
formed during chronic lymphocytic choriomeningitis infection can interfere with Fcg-receptor-mediated
effector activities, potentially contributing to immune dysfunction.Immune complexes (ICs) typically form
when polyclonal antibodies bind to poly-
valent antigens forming large antibody-an-
tigen complexes. While IC formation is an
inevitable consequence of an effective im-
mune response and is required for clear-
ance of pathogenic antigens, inappro-
priate generation and deposition of such
complexes results in pathology (Couser
and Salant, 1980). Thus, the generation
and clearance of immune complexes is a
tightly regulated process; perturbations in
immune complex clearance are associ-
ated with a variety of disease states due
to activation of innate and adaptive im-
mune cells within lymphoid organs or at
a site of infection through crosslinking
of Fcg receptors (FcgR). In this issue of
Immunity, papers by Weiland et al. and
Yamada et al. describe a phenomenon
whereby high amounts of IC formed during
chronic lymphocytic choriomeningitis
(LCMV) infection did not cause inflamma-
tory disease due to crosslinking of FcgRs;
instead, the IC were found to interfere with
immunoglobulin G (IgG)-mediated effector
functions by blocking FcgR interactions.
In the healthy host, IC production oc-
curs in response to acute events such as
infection, effectively restricting inflamma-
tory signaling to instances warranting anactive immune response. Cellular func-
tions involved in clearing infection are, in
part, mediated through FcgRs and in-
clude phagocytosis, antibody-dependent
cell cytotoxicity (ADCC), antigen presen-
tation, and selection of B cells during anti-
body responses (Pincetic et al., 2014).
Following resolution of an infection, ICs
are no longer generated and existing ICs
are rapidly cleared from circulation.
In contrast, persistent IC formation oc-
curs in a variety of chronic disease states
and can result in unregulated, prolonged
FcgR signaling when defects in IC clear-
ance are also present. Chronic diseases
with ICs are often of autoimmune, neo-
plastic, or infectious etiologies and occur
when antibody is continuously produced,
either appropriately (as in infection) or
inappropriately (as in autoimmune and
some neoplastic diseases), which reacts
with pathogen or host antigens. In these
settings, unchecked IC-FcgR interactions
can culminate in hallmark sequelae of
inflammatory diseases such as glomeru-
lonephritis, vasculitis, arthritis, and bone
erosion.
In addition to these classic inflamma-
tory manifestations, persistent ICs can
contribute to a broad range of abnormal-
ities in innate and adaptive immunity,including elevated type 1 interferon (IFN)
and dysregulated B and T cell functions.
Elevated Type 1 IFN concentrations are
sustained, in part, through TLR signaling
following FcgR-mediated IC uptake; hy-
peractivation of immune cells can result,
contributing to loss of peripheral toler-
ance, including increased autoantibody
production as is classically seen in sys-
temic lupus erythematosis, HIV, and in
Lyme arthritis following Borrelia burgdor-
feri infection. Persistent elevation of type
1 IFN can also have broad immunosup-
pressive effects resulting from induction
of the anti-inflammatory cytokine inter-
leukin-10 (IL-10) and/or upregulation of
programmed cell death ligand 1, an inhib-
itory coreceptor for T lymphocytes (Ban-
chereau and Pascual, 2006). Persistent
ICs are also associated with dysfunctional
lymphocyte populations; B cell abnormal-
ities are perhaps best characterized in
humans in HIV infection and can include
polyclonal activation (including of autor-
eactive specificities), suppressed anti-
viral IgA responses, and delayed or ab-
sent production of neutralizing antibodies
(Moir and Fauci, 2009). T cell ‘‘exhaus-
tion’’ in IC disease, characterized by
loss of effector function, is present in
several chronic human viral infectionsFebruary 17, 2015 ª2015 Elsevier Inc. 213
